March 2026 monthly delivery for hartwigmedical/actin focused on immunology reporting improvements (HLA-A) and robust disruption data handling. Implemented new display modes, inline content, extended regex, and refactored utilities; fixed NaN handling for undisrupted copy numbers, standardized NaN/null behavior across disruption data, and bumped the data model version to 2.11.0 to preserve compatibility. These changes improve reporting reliability, reduce downstream errors, and enhance data quality for downstream pipelines and decision-making.

February 2026 performance summary: Implemented and stabilized core ACTIN workflows, enhanced rerun reliability, and expanded immunology and fusion reporting capabilities. Delivered metadata-driven reference loading, improved run cleanup, and reference logging; reinforced rerun pipeline behavior to reduce failures; added ImmunologyGenerator to display HLA-A data in molecular reports and allowed optional 'N' suffix in HLA regex; introduced domainsKept and domainsLost for fusion annotations with end-to-end updates to extraction, annotation, and tests. Result: more deterministic runs, higher data integrity, improved clinical relevance of reports, and stronger test coverage.

Concise monthly summary for 2026-01 focusing on key features, major fixes, and impact in hartwigmedical/scripts. The month delivered end-to-end ACTIN cohort execution within the dataset loop with enhanced observability and dynamic log-directory resolution, plus batch processing and IO utilities enhancements. All changes were geared toward reliability, observability, and maintainability with clear business value.

December 2025 monthly summary for hartwigmedical/scripts. The month focused on delivering core business value through pipeline hardening, improved data handling, and expanded automation for Orange discovery and molecular cohort workflows. Key outcomes include faster, more reliable orange version discovery, enhanced WGS metrics processing, and robust data-cohort tooling with better observability and secrets security.

Month: 2025-11. This period delivered high-impact features and reliability improvements across two repositories (hartwigmedical/actin and hartwigmedical/scripts), driving better clinical data usability and more stable experiment workflows. Key features delivered: - Treatment Ranking Table Enhancements and Event Handling (ACTIN-2534) in hartwigmedical/actin: refactored for maintainability and performance; simplified event extraction; improved ranking logic to order by patient variant/event then group; updated tests and defaults to support new event structures. Commit reference: 4d3790e243058e1900f0dec8d761d53c7701fce4. - ACTIN Build Clinical Data Access and Logging Improvements in hartwigmedical/scripts: improved local JAR and directory path resolution; enhanced logging for cohort clinical record creation; fixes to directory output paths and function closures to ensure reliable ACTIN cohort data access. Commits include ACTIN-2784 and ACTIN-2891 series (multiple hashes listed in input). - EMC Experiment Execution Workflow Improvements in hartwigmedical/scripts: consolidated run workflow enhancements including directory navigation improvements, added directory listing visibility, improved logging for parameter errors, and cleaned up Java class path usage within EMC execution flow. Commits include ACTIN-2784 series. Major bugs fixed: - Path resolution and directory output issues in data access scripts; improved logging messages to surface failures and parameter errors; corrected event/test data alignment and directory-path related regressions; refined test data initialization to support new event structures. Overall impact and accomplishments: - Enabled more reliable access to ACTIN cohort data and robust cohort clinical record creation, reducing data-access related incidents. - Delivered faster, more accurate treatment ranking reports through structural refactors and clearer event handling. - Improved observability and maintainability across data pipelines and experiment workflows, reducing troubleshooting time and enabling more predictable experimentation. Technologies and skills demonstrated: - Refactoring for maintainability and performance; advanced logging and observability; path and classpath handling in Python/Java tooling; data-test alignment; scripting and automation improvements; cross-repo collaboration across actin and scripts.

October 2025 monthly summary for hartwigmedical/actin focusing on molecular evidence capabilities. Delivered targeted categorization and reporting improvements for Tumor Mutational Load (TML) and Microsatellite Instability (MSI). Refactored AggregatedEvidenceFactory to correctly handle molecular characteristics, introduced constants for stable and low variants, and updated aggregation logic to generate distinct evidence entries for positive and negative findings, improving accuracy and reporting of molecular evidence. Addressed recurrent TML/MSI warnings to reduce noise and improve reliability across downstream reports.

September 2025 monthly summary for hartwigmedical/actin focused on the Molecular Panel Testing module. Delivered a targeted refactor by consolidating test constants into a single source of truth and removing an unused function, improving test setup reliability and maintainability with minimal risk.